On the mechanism of action of recombinant activated factor VII administered to patients with severe thrombocytopenia and life-threatening haemorrhage: Focus on prothrombin activation

British Journal of Haematology

Volumn 117, Issue 3, 2002, Pages 705-708

  Gerotziafas, Grigoris T ^a,b,c   Zervas, Kostas ^a   Arzoglou, Pantelis ^b   Karavaggeli, Eli ^d   Parashou, Stella ^b   Van Dreden, Patrick ^e   Christakis, John ^a   Samama, Meyer Michel ^c  

^a THEAGENIO CANCER HOSPITAL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c HÔTEL DIEU   (France)

^d Agios Dimitrios General Hospital   (Greece)

^e Serbio Research Laboratory   (France)

Author keywords

Haemorrhage; Prothrombin; Recombinant factor VIIa; Thrombin generation; Thrombocytopenia

Indexed keywords

BLOOD CLOTTING FACTOR 7; CITRIC ACID; PROTHROMBIN ANTIBODY; THROMBIN;

ARTICLE; BLEEDING; BLEEDING TIME; BLOOD CLOT RETRACTION; BLOOD CLOTTING; CASE REPORT; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; PARTIAL THROMBOPLASTIN TIME; PLASMA; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE; THROMBOCYTOPENIA; WESTERN BLOTTING;

BLOTTING, WESTERN; FACTOR VII; HEMORRHAGE; HEMOSTASIS; HUMANS; PARTIAL THROMBOPLASTIN TIME; PLATELET COUNT; PROTHROMBIN; PROTHROMBIN TIME; RECOMBINANT PROTEINS; THROMBIN; THROMBOCYTOPENIA;

EID: 0036098770     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03437.x     Document Type: Article

References (11)

1. Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage
2. Phenotyping the clotting system
3. Activated factor VII activates factors IX and X on the surface of activated platelets: Thoughts on the mechanism of action of high dose activated FVII
4. High dose factor VIIa increases initial thrombin generation and mediates platelet activation in thrombocytopenia-like conditions in a cell-based model system
5. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia
6. Platelet activity of high dose factor VIIa is independent of tissue factor
7. Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders
8. Recombinant factor VIIa in severe uremic bleeding
9. Clinical experience with activated factor VII: Focus on safety aspects
10. Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors
11. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II